Fairman Group LLC Has $6.16 Million Stock Holdings in Accolade, Inc. (NASDAQ:ACCD)

Fairman Group LLC raised its position in Accolade, Inc. (NASDAQ:ACCD) by 58.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,802,399 shares of the company’s stock after purchasing an additional 665,112 shares during the quarter. Accolade accounts for approximately 5.1% of Fairman Group LLC’s holdings, making the stock its 3rd largest holding. Fairman Group LLC’s holdings in Accolade were worth $6,164,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ACCD. Mission Creek Capital Partners Inc. acquired a new stake in shares of Accolade during the 3rd quarter worth $38,000. Pallas Capital Advisors LLC acquired a new stake in Accolade during the fourth quarter worth about $38,000. IQ EQ FUND MANAGEMENT IRELAND Ltd acquired a new stake in Accolade during the third quarter worth about $46,000. Wolverine Trading LLC bought a new position in Accolade in the 3rd quarter valued at about $51,000. Finally, Point72 Asia Singapore Pte. Ltd. raised its position in shares of Accolade by 1,144.1% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 20,913 shares of the company’s stock valued at $81,000 after buying an additional 19,232 shares in the last quarter. 84.99% of the stock is currently owned by institutional investors and hedge funds.

Accolade Stock Down 0.3 %

Shares of NASDAQ:ACCD opened at $6.87 on Wednesday. The company has a current ratio of 2.63, a quick ratio of 2.63 and a debt-to-equity ratio of 0.67. The stock has a fifty day simple moving average of $5.11 and a two-hundred day simple moving average of $4.27. Accolade, Inc. has a 12-month low of $3.08 and a 12-month high of $13.93. The stock has a market capitalization of $560.50 million, a price-to-earnings ratio of -3.05 and a beta of 2.20.

Accolade (NASDAQ:ACCD) last posted its quarterly earnings results on Friday, January 10th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. Accolade had a negative net margin of 40.36% and a negative return on equity of 20.74%. On average, research analysts anticipate that Accolade, Inc. will post -1.2 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Rajeev Singh sold 13,357 shares of the business’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $3.60, for a total value of $48,085.20. Following the transaction, the chief executive officer now owns 814,316 shares of the company’s stock, valued at approximately $2,931,537.60. The trade was a 1.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 40,145 shares of company stock valued at $157,917 in the last quarter. 8.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities analysts recently commented on ACCD shares. Needham & Company LLC reissued a “hold” rating on shares of Accolade in a research note on Wednesday, January 8th. Stifel Nicolaus reissued a “hold” rating and set a $7.03 target price (down previously from $8.00) on shares of Accolade in a research report on Thursday, January 9th. William Blair downgraded Accolade from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Raymond James restated a “market perform” rating on shares of Accolade in a report on Thursday, January 9th. Finally, Leerink Partnrs downgraded shares of Accolade from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, January 8th. Twelve research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, Accolade has an average rating of “Hold” and a consensus price target of $7.55.

Accolade Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.